Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan-based Conditioning for SCID Stem Cell Transplant
NCT04370795Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan in severe combined immunodeficiency (SCID), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Nov 2025; status: withdrawn.
02
Drugs
busulfan
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT04370795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370795.